Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future.

All of RECERCAT

To access the full text documents, please follow this link: http://hdl.handle.net/10230/26791

dc.contributor.author	Muntasell i Castellví, Aura, 1972-
dc.contributor.author	López-Botet, Miguel
dc.date	2016
dc.identifier.citation	Muntasell A, López-Botet M. Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future. Clin Cancer Res. 2016 Apr 15;22(8):1831-3. doi: 10.1158/1078-0432.CCR-15-3168
dc.identifier.citation	1078-0432
dc.identifier.citation	http://dx.doi.org/10.1158/1078-0432.CCR-15-3168
dc.identifier.uri	http://hdl.handle.net/10230/26791
dc.format	application/pdf
dc.language.iso	eng
dc.publisher	American Association for Cancer Research
dc.rights	info:eu-repo/semantics/embargoedAccess
dc.rights	© American Association for Cancer Research (AACR) http://dx.doi.org/10.1158/1078-0432.CCR-15-3168
dc.subject	Leucèmia mieloide aguda
dc.title	Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future.
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/acceptedVersion
dc.description.abstract	The report by Curti et al. highlightsthe potential of NK cell-based adoptive cellular immunotherapy in oncology,currently boosted by advances in the knowledge on NK cell biology and in their ex-vivo GMP manipulation.Several issues deserve attention to fully achieve the translation of these advances to the clinic.